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Edited by Felix WielandAbstract Here, we identify ADP-ribosylation factor (ARF)-
like 7 (ARL7) as the only ARF- and ARL-family member whose
mRNA-expression is induced by liver X-receptor/retinoid X-
receptor agonists or cholesterol loading in human macrophages.
Moreover, subcellular distribution of mutant and wild type
ARL7-enhanced green ﬂuorescent protein (EGFP) supports that
ARL7 may be involved in a vesicular transport step between a
perinuclear compartment and the plasma membrane. Therefore,
we investigated the eﬀect of ARL7 over-expression on the
cholesterol secretory pathway. We found that expression of wild
type and dominant active ARL7-EGFP stimulated the rate of
apolipoprotein AI-speciﬁc cholesterol eﬄux 1.7- and 2.8-fold. In
contrast, expression of the dominant negative form of ARL7-
EGFP led to 50% inhibition of cholesterol eﬄux. This data is
consistent with a model in which ARL7 is involved in transport
between a perinuclear compartment and the plasma membrane
apparently linked to the ABCA1-mediated cholesterol secretion
pathway.
 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Transport1. Introduction
Cellular lipid content and distribution is tightly controlled at
the stages of lipoprotein uptake, lipid synthesis, sorting, stor-
age, and export [1]. ATP-binding cassette transporter ABCA1
controls removal of excess cholesterol by high density lipo-
proteins (HDL), the initial step of ‘‘reverse cholesterol trans-
port’’ (RCT) [2–4]. The RCT pathway is essential for virtually
all cells but especially for the macrophage which is subject to* Corresponding author. Fax: +49-251-83-56205.
E-mail address: engeltho@uni-muenster.de (T. Engel).
Abbreviations: ABC, ATP binding cassette; acLDL, acetylated low
density lipoprotein; apo, apolipoprotein; ATP, adenosine triphos-
phate; EGFP, enhanced green ﬂuorescent protein; HDL, high density
lipoprotein; LDL, low density lipoprotein; PCR, polymerase chain
reaction; RCT, reverse cholesterol transport; wt, wild type
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to uptake and degradation of dead and apoptotic cells as well
as modiﬁed lipoproteins. The transformation of macrophages
to foam cells is thought to initiate atherosclerotic plaque for-
mation in the arterial wall which may end in coronary heart
disease and stroke, the most prominent causes of death in the
western world [5].
ApoAI and HDL are extracellular acceptors for excess cho-
lesterol. Tangier disease, a rare autosomal disease caused by
mutations inABCA1, is characterized by complete lack ofHDL
and massive foam-cell formation, primarily in the reticulo-en-
dothelial system, due to defective lipid export capacity of the
macrophage [6–8]. The precise molecular mechanism of HDL-
formation by ABCA1 needs further clariﬁcation. Since vesicu-
lar transport mediates some part of cellular cholesterol trans-
port, it may be assumed that cholesterol traﬃcking to the
plasma membrane depends on target-speciﬁc vesicular trans-
port systems which mediate cholesterol ﬂux from intracellular
pools to ABCA1 located at the plasma membrane and recycling
endosomes. ADP-ribosylation factors (ARFs) represent Ras-
related small regulatory GTPases which control vesicular
transport in the secretory and endosomal pathway at the stage
of vesicle budding [9]. In addition, members of this family
regulate various cellular functions such as cytoskeleton for-
mation/remodelling or the activity of phospholipase D [10–12].
ARF-like proteins (ARLs) are thought to have a similar func-
tion [13]. The aim of the present study was to identify ARLs or
ARFs which may be involved in cholesterol transport upon
ABCA1-meditated cholesterol secretion. Our results indicate
that, among a great variety of ARFs and ARLs, ARL7, which
was cloned initially as a GTPase with rapid nucleotide exchange
and a putative nuclear function [14], is the only family member
whose expression is induced signiﬁcantly by liver X-receptor
(LXR) and retinoid X-receptor (RXR) agonists (T0901317 and
RO-26-4456) or cholesterol-loading. Since this regulation im-
plied that ARL7 may be involved in RCT, we studied its in-
tracellular traﬃcking and the eﬀect of several ARL7mutants on
apoAI-dependent cholesterol eﬄux. The results of these studies
supported an involvement of ARL7 in RCT. We currently
presume that ARL7 contributes to a vesicular transport step
between a perinuclear compartment and an ABCA1 accessible
cholesterol pool at the plasma membrane.blished by Elsevier B.V. All rights reserved.
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2.1. Reagents and cells
LXR and RXR agonist T0901317 and RO-26-4456, respectively,
were kindly provided by F. Hoﬀmann La-Roche, Basel, and used at a
concentration of 0.1 and 1 lM, respectively. Anti-ARF6 monoclonal
antibody (clone 3A1) was purchased from Santa Cruz Biotechnology.
Acetylated low density lipoprotein (acLDL) was prepared and human
monocytes were obtained and maintained as previously described [15].
HeLa cells (DSMZ) were maintained in DMEM/10% FCS/penicillin
(100 units/ml)/streptomycin (0.1 mg/ml) in a humidiﬁed incubator at
37 C and 5% CO2.
2.2. Quantitative real-time PCR assay
Assays were performed as previously described [15] using a Gene-
Amp 7900HT sequence detection system (ABI). The following as well
as established [15] primer pairs were used for ampliﬁcation: ARF1, 5
0
-
CAGACTGCGATCAATTCTGC-3
0
, 5
0
-GACAAGCACATGGCTA
TGGA-3
0
; ARF2, 5
0
-AATAACACCTTCGCTGTCTGG-3
0
, 5
0
-AAG
TGAGCCTTGATGTG TGC-3
0
; ARF3, 5
0
-TGCAAACAAACAGG
ATCTGC-3
0
, 5
0
-ACCAGTTACGGTGACGAAGG-3
0
; ARF4, 5
0
-GA
CTCCTGGCCTACATCAGC-3
0
, 5
0
-CAATTCTTTGCAACCAG-
CAC-3
0
; ARF5, 5
0
-AGAAGCAGATGCGGATTCTC-3
0
, 5
0
-TAT-
GGTTGGGATGGTGGTG-3
0
; ARF6, 5
0
-TTGTTGGCT TTGCG
TTAGG-3
0
, 5
0
-TTCCCATTCTGCTGGAAGTC-3
0
; ARL1, 5
0
-CAC
TTGGGTTACCTGCCTTG-3
0
, 5
0
-AACCATTCCATTGCCTCATC-
3
0
; ARL2, 5
0
-GGCTCCTGACCATT CTGAAG-3
0
, 5
0
-TCAGGAT
GGTTGTCTTTCCAG-3
0
; ARL3, 5
0
-GACATCAGCCACATCACA
CC-3
0
, 5
0
-TCCTCTGTCCA CCAATGTCC-3
0
; ARL4, 5
0
-TAG-
CAATGGGTGAACTGAGC-3
0
, 5
0
-CCTTCCTTTAGGCCATCTC
C-3
0
; ARL5, 5
0
-GCC AAGGACTTGAATGGATG-3
0
, 5
0
-GCA
GCTTTCAGGTAAAGTCCAG-3
0
; ARL6, 5
0
-AGAAGGCTTGCA
AGAAGGTG-3
0
, 5
0
-TTGAAAATTGCTGAGGTTTCC-3
0
; ARL7,
5
0
-ATGGATGGATGAGCGAGAAC-3
0
, 5
0
-CATTTGGGTGCAG
AGATTCC-3
0
.
2.3. 3
0
-RACE
Total RNA was isolated as described [15]. 3
0
-RACE was performed
using the 3
0
-RACE system according to the manufacturers guidelines
(Invitrogen) with a gene-speciﬁc primer 5
0
-CTTCAACACCGAGAA-
GATCAAGCTG-3
0
in the coding sequence of the open reading frame
of the ARL7 cDNA. Polymerase chain reaction (PCR) products ob-
tained were puriﬁed on columns (Qiagen) and sequenced directly using
the ABI PRISM BigDyeTM Terminators v2.0 Cycle Sequencing Kit
(ABI). Sequencing reactions were separated on an ABI-PRISM 3700
DNA Analyzer (ABI).
2.4. Expression of ARL7 in HeLa cells
Coding sequence of ARL7 with Kozak consensus sequence and
lacking a stop codon was ampliﬁed from human macrophage cDNA
with ﬂanking BamHI and HindIII restriction sites and inserted in
frame with enhanced green ﬂuorescent protein (EGFP) into pEGFP-
N1 vector (Clontech). Point mutations were introduced using Quik-
Change Kit according to the manufacturers guidelines (Stratagene).
All ampliﬁed sequences were veriﬁed by DNA sequencing, as described
above. For transient expression experiments 1.6 106 trypsinized
HeLa cells in 0.4 ml DMEMwere transfected with 10 lg plasmid DNA
using an electroporator equipped with a capacitance extender (Gene-
Pulser II, BioRad) at 975 lF and 230 V. Cells were seeded on six 12
mm diameter cover slips in 24-well dishes and ﬁxed with 4% PFA in
PBS 12–48 h post-transfection. Cover slips were mounted on cover
slides using Mowiol and viewed with a Zeiss Axioskop equipped with a
CCD camera and ﬂuorescein ﬁlter set. Images were processed using
Adobe Photoshop 7.0. Stable transfections were performed as above
with 4 106 cells in 0.4 ml DMEM. Cells were seeded in ten tissue
culture dishes with 15 cm diameter. For selection 0.5 mg/ml G418
(Gibco) was added to complete medium. Medium was changed every
3–4 days. Single clones were selected after 3 weeks using cloning cyl-
inders (Bellco Glass), and screened by ﬂuorescence microscopy and
Western-blot analysis using our polyclonal ARL7 antibody.
2.5. Polyclonal ARL7 antibody
Synthetic peptides corresponding to aa 144–159 and 168–182 of
human ARL7, respectively, containing a cysteine at the amino-termi-
nal position were synthesized and coupled to keyhole limpet hemo-cyanine. Rabbits were immunized with a mixture of both immunogens
using the DoubleX-Service (Eurogentec). Speciﬁc IgGs were puriﬁed
from the antiserum according to established procedures [16] using a
matrix consisting of antigen coupled to Sulfolink-beads (Pierce).
Antibodies were biotinylated using the Biotin Labeling Kit (Roche
Diagnostics).
2.6. Immune-precipitations
Ten million cells were washed with PBS and scraped oﬀ the plate in
ice cold lysis buﬀer (0.3 M NaCl/0.1 M Tris/HCl, pH 7.4/2% Triton X-
100/1% sodium deoxycholate) supplemented with Complete protease
inhibitor cocktail (Roche). Cells were lysed for 1 h on ice in lysis buﬀer.
Subsequent steps were performed at 4 C on a rotating wheel. Su-
pernatants were obtained (30 min 30 000 g, JA20, Beckman), an
equal volume of water was added and supernatants were precleared for
1 h using protein G-Sepharose4B beads (Amersham). Antigen was
immune-precipitated by incubating the supernatants with IgGs pre-
bound to protein G-Sepharose4B beads for 2 h. Beads were harvested
and washed according to the manufacturers guidelines (Immune-pre-
cipitation Kit, Roche) and processed for Western-blot analysis.
2.7. Western-blot analysis
Samples were lysed in Laemmli sample buﬀer supplemented with -
mercaptoethanol and separated on 12.5% SDS–PAGE gels [17]. Pro-
tein was transferred onto Protran nitrocellulose ﬁlters (Schleicher &
Schuell). For detection with HRP-labeled secondary antibody 5% dry
skim milk in PBS/0.1% Tween 20 was used for blocking the ﬁlter and
for antibody incubations, for detection of biotinylated antibody 2.5%
BSA in PBS/0.1% Tween 20 was used instead. For detection horse-
radish peroxidase-labeled secondary antibody (BioRad) or horseradish
peroxidase-streptavidin, respectively, ECL system and Hyperﬁlm ECL
was used (Amersham). Developed ﬁlms were scanned and quantiﬁed
using ImageJ software (http://rsb.info.nih.gov/ij/).
2.8. Cholesterol eﬄux measurement
Cells were grown in a 24-well tissue culture plate. Conﬂuent cells
were labeled overnight with 0.5 ml/well of DMEM/0.2% BSA/1 lM
T0901317/100 nM RO-26-4456 containing 2 lCi [3H]-cholesterol
(NEN-DuPont) per well. Cells were washed on ice with cold DMEM/
0.5% BSA and DMEM twice for 5 min each. 0.3 ml eﬄux medium
consisting of DMEM/0.2% BSA/1 lM T0901317/100 nM RO-26-4456
with or without 10 lg apolipoprotein AI was added for 4 h. Medium
was harvested, cells were removed by centrifugation and radioactivity
of an 0.25 ml aliquot was determined. Cells were lysed by adding 0.25
ml 0.1 M NaOH/0.15 M NaCl. After 10 min lysates and centrifuged
cells were collected in scintillation vials, plates were washed again with
0.25 ml 0.1 M NaOH/0.15 M NaCl and radioactivity of the samples
was determined. The fractional apoAI speciﬁc cholesterol eﬄux was
determined and normalized to the value obtained for HeLa cells.3. Results
3.1. Diﬀerential expression analysis
As candidates for diﬀerential expression analysis we chose
members of the ARF and ARF-like family, which may be
involved in vesicular transport steps within the cell requiring
coat protein assembly [9]. The study was performed using re-
verse transcription quantitative real-time PCR at diﬀerent
cholesterol loading states of the macrophage. acLDL was used
for cholesterol-loading, 2-hydroxypropyl-b-cyclodextrin for
cholesterol-depletion. As shown in Fig. 1, ARL7 was the only
studied family member which showed a direct and strong re-
sponse to cholesterol loading. The expression level of ARL7
mRNA was induced further by applying synthetic agonists
speciﬁc for the nuclear receptors LXR and RXR and was re-
pressed by cellular sterol unloading with 2-hydroxypropyl-b-
cyclodextrin. Such an expression pattern is similar to that
observed for the cellular lipid exporters ATP-binding cassette
transporter family members ABCA1 and ABCG1 [15,18]. The
Fig. 1. ARL7 gene expression is sterol sensitive. Human monocyte-derived macrophages were incubated for 24 h without added substance (light
grey), and in the presence of 80 lg acetylated LDL/ml (grey), synthetic LXR and RXR agonists (white) or 2% 2-hydroxypropyl-b-cyclodextrin
(black), respectively. Quantitative real-time PCR analysis was performed, as described in Section 2. Expression changes for transcripts of ARL7 as
well as for its family members ARL1–6, ARF1, -3, -5, -6, and ABC transporters ABCA1 and ABCG1 as well as glyceraldehyde-3-phosphate-de-
hydrogenase (GAPDH) as a housekeeping gene are shown. Samples were measured as triplicates and standard errors are given as error bars.
T. Engel et al. / FEBS Letters 566 (2004) 241–246 243range of expression observed for the ARL7 transcript was a
diﬀerence of 5.87 0.12 cycles at threshold corresponding to a
58.5-fold (1.1-fold) expression diﬀerence. Most of the other
ARF-family members showed almost no or the opposite reg-
ulation, especially during cholesterol removal.
High density DNA array analysis with Hu35KsubA-D and
HuGeneFl chip set (Aﬀymetrix) that was performed to obtain
a comprehensive set of data on cholesterol-dependent gene
regulation in human macrophages (Hobohm and Pech, un-
published) conﬁrmed the real-time quantitative PCR results.
Features on the chip surface corresponding to GenBank Ex-
pressed Sequence Tag (EST)-clone AA213410, presumably
corresponding to the 3
0
-end of the human ARL7 cDNA, dis-
played the same expression behavior. 3
0
-Rapid ampliﬁcation of
cDNA end (3
0
-RACE) analysis conﬁrmed that EST-clone
AA213410 is part of the ARL7 cDNA. The corresponding
sequence was deposited as Acc. AJ579851 in the EMBL nu-
cleotide database. Reverse transcription quantitative real-time
PCR using primer pairs speciﬁc for ampliﬁcation of AA213410
conﬁrmed 3
0
-RACE results as identical cycles at threshold
values and expression diﬀerences were observed for target re-
gions in the coding sequence and the 3
0
-end of the ARL7-
cDNA (not shown).
In order to test whether expression changes at the mRNA-
level propagate to the protein level, we performed immune-
precipitations using extracts from HeLa cells incubated with or
without either LDL or synthetic LXR/RXR agonists, respec-
tively. Enrichment of ARL7 by immune-precipitation was
required since our ARL7 antibody was not sensitive enough to
detect the endogenous ARL7 protein. As shown in Fig. 2,ARL7 protein was detected at the expected molecular weight
of 24 kDa. Incubation of HeLa cells with LDL increased
ARL7 protein content 1.8-fold and application of LXR/RXR
agonist induced it further (3.2-fold compared to untreated
cells), consistent with the changes of ARL7-mRNA. As a
control, ARF6 protein content was not inﬂuenced by incuba-
tion with LDL or LXR/RXR agonist.
3.2. Expression studies
For functional characterization of ARL7 we generated a
set of vectors allowing expression of ARL7-EGFP fusion
proteins containing the wild type (wt) or mutant ARL7
sequences. ARL7(G2A) lacks a myristoylation site,
ARL(T27N) represents the inactive GDP-bound (dominant
negative) and ARL7(Q71L) the active GTP-bound state
(dominant active). As shown in Fig. 3, wt and mutant ARL7-
EGFP fusion proteins were transiently expressed in HeLa
cells to the same extent. Our anti-ARL7 antibody detected
the fusion proteins at the expected molecular weight of 50
kDa in all cases.
When detecting GFP epiﬂuorescence of ARL7-EGFP ex-
pressing cells, a characteristic phenotype was the change in
HeLa cell morphology: When wt ARL7-EGFP was expressed,
green staining was detected within the cells and many intensely
stained ﬁlopodia formed at the periphery of the cell, indicating
interaction of ARL7 with components of the cytoskeleton
(Fig. 4A). Filopodia and their intense labeling disappeared
when cytochalasin D was added to the cells, whereas noco-
dazole had no eﬀect (not shown). Thus, ARL7 is presumably
involved in actin ﬁlament assembly and/or reorganization.
Fig. 2. ARL7 protein expression parallels mRNA expression. HeLa-
cells were grown in complete medium without, with LDL or with
synthetic LXR and RXR agonists for 24 h. Cells were harvested and
processed for immune-precipitation analysis. Western blots were per-
formed with a biotinylated rabbit anti-ARL7 antibody followed by
streptavidin-horseradish peroxidase. ARL7 protein is detected at 24
kDa. As loading control IgG light chain of the anti-ARL7 antibody
was detected using anti-rabbit IgG-horseradish peroxidase. ARF6 was
detected in an aliquot of the cells used for the immune-precipitation
and is not diﬀerentially expressed.
Fig. 3. Expression of ARL7-EGFP fusion proteins. HeLa-cells were
transiently transfected with constructs coding for EGFP alone or for
ARL7-EGFP-fusion proteins for 24 h. Western blots were performed
with a rabbit anti-ARL7 antibody and goat anti-rabbit horseradish
peroxidase. ARL7-EGFP-fusion protein is detected at 50 kDa.
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plasmic localization, most likely since it lacked its membrane
attachment site (Fig. 4B). This mutation also inactivated the
protein with respect to its eﬀect on the cytoskeleton. The T27N
mutant was present mainly on small punctate structures in the
perinuclear region of the cell and did not lead to ﬁlopodia
formation (Fig. 4C). Conversely, the Q71L mutant resulted in
a very similar staining pattern and aﬀected the cellular mor-
phology the same way as wt ARL7 with less ﬁlopodia
(Fig. 4D).Fig. 4. Subcellular distribution of wt and mutant ARL7-EGFP fusion proteins Human ARL7 fused to EGFP was transiently expressed in HeLa cells
for 24 h. (A) ARL7(wt), (B) ARL7(G2A), (C) ARL7(T27N), (D) ARL7(Q71L). Cells were ﬁxed and epiﬂuorescence was recorded. Scale bars
represent 10 lm.
Fig. 5. Eﬀect of ARL7 on cellular cholesterol eﬄux. HeLa cells either
untransfected or stably expressing wt and mutant ARL7-EGFP fusion
proteins or EGFP were used for cholesterol eﬄux measurements as
described in Materials and Methods. Triplicate measurements were
performed.
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Given this intracellular localization pattern, we next studied
whether ARL7 may play a role in cellular cholesterol export.
For these studies, we generated a series of HeLa cell lines
stably expressing the above mentioned ARL7-EGFP fusion
proteins. These lines were labeled with [3H]-cholesterol and
incubated in the presence or absence of apoAI with eﬄux
medium containing BSA, 1 lM of T0901317 and 0.1 lM of
RO-26-4456. Subsequently, radioactivity was determined in
the medium and cell lysates and the fractional apoAI speciﬁc
cholesterol eﬄux was evaluated as described in Section 2. As
shown in Fig. 5, expression of wt ARL7-EGFP led to a
moderate stimulation of the fractional apoAI speciﬁc choles-
terol eﬄux (1.7-fold, p < 0:05). Expression of dominant-
active ARL7 resulted in more pronounced stimulatory eﬀect
(almost 3-fold stimulation, p < 0:001). In contrast, the domi-
nant negative form inhibited the fractional apoAI speciﬁc
cholesterol eﬄux by 50% (p < 0:001). Moreover, EGFP as
well as ARL7(G2A)-EGFP used as controls had no eﬀect.4. Discussion
The results of this study support that an ARF-like protein,
ARL7, may play a role in cellular cholesterol secretion. Ac-
cording to this concept, ARL7 would participate in the path-
way which enables the cell to export cholesterol when the
cellular level of cholesterol is rising and cholesterol secretion is
necessary in order to protect the cell from the devastating ef-
fects resulting from cholesterol overloading. We could dem-
onstrate that ARL7 expression is regulated in a coordinate
manner with other components of the cholesterol secretion
machinery, especially ABCA1. It is conceivable that eﬃcient
cholesterol export depends on eﬃcient transport of cholesterol
from intracellular pools to the plasma membrane where it is
desorbed either non-speciﬁcally into the extracellular space or
transferred in a speciﬁc manner onto apolipoproteins or na-
scent lipoprotein particles via the ABCA1-pathway [1,19–21].
Hence, simultaneous upregulation of ABCA1 and ARL7 mayprovide a useful mechanism to increase the capacity of the cell
to transfer excess cholesterol to an ABCA1-accessible choles-
terol pool at or close to the plasma membrane.
Since dominant active and wt ARL7 strongly stain ﬁlopodia
the assumption that ARL7 is involved in traﬃcking towards
the plasma membrane is supported by our results in analogy to
similar data on ARF6 [22–24]. Dominant negative ARL7 re-
sides on perinuclear structures which lets us assume that these
structures are the starting point of ARL7-mediated transport
vesicle formation, similarly as was proposed for dominant
negative ARF6 [23].
Since we could demonstrate that ARL7-mediated stimula-
tion of cholesterol secretion depended on the presence of
apoAI it seems likely that ARL7 acts in concert with ABCA1.
According to previous studies, ABCA1 is transported on a
retroendocytic route in a variety of cell types [25,26]. In ad-
dition, uptake and resecretion of apolipoproteins that interact
with ABCA1 has been reported [20,27–29]. Thus, it is possible
that some of the eﬀects of ARL7 on apoAI-dependent cho-
lesterol eﬄux are in fact secondary to modulation of ABCA1
transport or other means, such as altered half life of ABCA1 or
modulation of apoAI and/or ABCA1 endocytic transport.
Clearly, further studies will be required in order to evaluate
these possibilities.
Moreover, some caution must remain with respect to the in-
terpretation of our data. Over-expression of the two ARL7
forms (ARL7-EGFP and ARL7(Q71L)-EGFP) which stimu-
lated cholesterol eﬄux were associated with quite extensive al-
terations of cell morphology.Most strikingwas the formation of
ﬁlopodia, implying that ARL7 over-expression altered cyto-
skeleton assembly and/or remodeling. We presume that some of
these changes may have been due to accumulation of ARL7-
EGFP and ARL7(Q71L)-EGFP at the terminus of their trans-
port route, presumably as a consequence of a very slow return to
their starting point. The latter eﬀect may have been caused by a
limited supply of ARL7-speciﬁc eﬀectors (e.g. GTPase activat-
ing protein, GAP), or changes in the kinetics of intracellular
transport routes resulting from over-expression in a similar
manner as was proposed in the case of ARFs by D’Souza-
Schorey [23]. One very obvious consequence resulting from ﬁl-
opodia formation was a considerable increase of the cell surface
area. This may have increased the eﬃciency by which apoAI
extracted cholesterol from cholesterol-rich microdomains at the
level of the plasma membrane essentially in an artifactual
manner. However, our observation that the quite signiﬁcant
inhibition of cholesterol eﬄuxwhich resulted from expression of
the dominant negative form of ARL7 occurred in the absence of
any detectable changes of cell morphology supports the speci-
ﬁcity of the ARL7-mediated eﬀect very strongly. Thus, we think
that it is justiﬁed to conclude that ARL7 contributes to apoAI-
dependent cholesterol secretion in a speciﬁc manner.
The present results on intracellular localization and traf-
ﬁcking of ARL7 diﬀer from a previous study which led to the
assumption that ARL7 may be located in the nucleus [14]. This
assumption based on the use of a synthetic construct consisting
of GFP fused to the last 20 amino acids of the ARL7 carboxy-
terminus. This peptide exhibits similarity to nuclear localiza-
tion signals because it contains nine arginine or lysine residues.
In contrast to the previous study, we used the full length ARL7
sequence fused at the carboxy-terminus to EGFP. None of the
various ARL7-EGFP fusion constructs that were used in our
study were able to direct a signiﬁcant fraction of the fusion
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by immunocytochemistry that a fraction of ARL4, which is a
close relative of ARL7, is in fact located in the nucleus of
cultured Sertoli and neuroblastoma cells [14,30]. Thus, it
cannot be excluded at present that the EGFP fusion at the
carboxy-terminus of ARL7 that was used in our study inhib-
ited its import into the nucleus. Nevertheless, in the case of
ARL4, a signiﬁcant fraction of the protein could be found
associated with the cytoplasmic vesicle fraction in addition to
its nuclear localization. According to our data the situation
appears to be similar for ARL7, because we could demonstrate
that a signiﬁcant fraction of the ARL7 protein is targeted to a
cytoplasmic vesicle fraction destined to be transported to the
plasma membrane.
Currently, it is not entirely clear how various mammalian
ARLs are targeted to their correct destinations in the cell.
However, it was shown recently for two yeast ARLs, Arl1p
and Arl3p, that Golgi localization of Arl1p is regulated via a
cascade in which the GTPase cycle of Arl3p regulates Golgi
localization of Arl1p [31]. Thus, it is conceivable that the
GTPase cycle domain may be an essential structural require-
ment for ARL targeting in a physiological context. Moreover,
it is evident from our results obtained with the myristoylation-
defective mutant ARL7(G2A)-EGFP that ARL7 myristoyla-
tion is essential for its recruitment to cytoplasmic vesicles.
Thus, we think that our strategy to use EGFP fusions with the
full length ARL7 sequence provides a good indication for
ARL7 targeting and traﬃcking under in vivo conditions.
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